Y-mAbs Therapeutics, Inc. (YMAB) News
Filter YMAB News Items
YMAB News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
YMAB News Highlights
- YMAB's 30 day story count now stands at 2.
- Over the past 1 day, the trend for YMAB's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about YMAB are DEC.
Latest YMAB News From Around the Web
Below are the latest news stories about Y-MABS THERAPEUTICS INC that investors may wish to consider to help them evaluate YMAB as an investment opportunity.
Y-mAbs Therapeutics Added to the NASDAQ Biotechnology IndexNEW YORK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced it will be added to the NASDAQ Biotechnology Index (NASDAQ: NBI), effective prior to the market open on Monday, December 18, 2023. The NASDAQ Biotechnology Index is designed to track the performance of |
Director Biotech Wg's Strategic Investment in Y-mAbs Therapeutics IncY-mAbs Therapeutics Inc (NASDAQ:YMAB), a commercial-stage biopharmaceutical company, has recently witnessed a significant insider purchase that has caught the attention of investors and market analysts alike. |
Director Biotech Wg's Strategic Investment in Y-mAbs Therapeutics Inc (YMAB)Y-mAbs Therapeutics Inc (NASDAQ:YMAB), a commercial-stage biopharmaceutical company, has recently witnessed a significant insider purchase that has caught the attention of investors and market analysts alike. |
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q3 2023 Earnings Call TranscriptY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q3 2023 Earnings Call Transcript November 14, 2023 Operator: Good morning and welcome to Y-mAbs Therapeutics Third Quarter 2023 Earnings Conference Call. Please note that today’s event is being recorded. At this time, all participants are in a listen-only mode. Instructions for the question-and-answer session will follow after the prepared remarks. […] |
Q3 2023 Y-mAbs Therapeutics Inc Earnings CallQ3 2023 Y-mAbs Therapeutics Inc Earnings Call |
Y-mAbs Therapeutics Inc (YMAB) Reports Strong Revenue Growth Amidst Operational StreamliningQ3 2023 Earnings Highlight Robust Sales and Extended Cash Runway |
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue EstimatesY-mAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of -12.50% and 0.53%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock? |
Y-mAbs Reports Third Quarter 2023 Financial Results and Recent Corporate DevelopmentsQ3 2023 DANYELZA® net product revenues of $20.0 million represents YoY growth of 59%U.S. FDA clearance of IND for CD38-SADA for relapsed or refractory non-Hodgkin LymphomaCash and cash equivalents of $86.6 million as of September 30, 2023, with anticipated cash runway extended into 2027Management updates FY 2023 financial guidance by lowering anticipated operating expenses and use of cash The Company will host a conference call on Tuesday, November 14, 2023, at 9:00 a.m. ET NEW YORK, Nov. 13, 20 |
Investors in Y-mAbs Therapeutics (NASDAQ:YMAB) have unfortunately lost 89% over the last three yearsEvery investor on earth makes bad calls sometimes. But you want to avoid the really big losses like the plague. So... |
All You Need to Know About Y-mAbs Therapeutics, Inc. (YMAB) Rating Upgrade to Strong BuyY-mAbs Therapeutics, Inc. (YMAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). |